Sports

Spanish Olympic striker Rafa Mir signs for Sevilla

Aug 21, 2021

Madrid (Spain), August 21: Spanish La Liga club Sevilla have strengthened their attack with the signing of striker Rafa Mir from Wolverhampton.
Mir joins Sevilla after spending 18-months on loan with Huesca, helping them earn promotion to La Liga and last season scoring 13-league goals in the Spanish top flight.
Those goals earned him a place in the Spain squad which won the silver medal in the Tokyo Olympic Games and he scored a hat-trick against Cote d'Ivoire in the quarterfinals of the tournament.
The 24-year-old had also been linked with a move to reigning La Liga champions Atletico Madrid, who are looking to sign a striker to support veteran Luis Suarez.
Mir announced his departure from Wolves in a post on social media. "The time has come to say goodbye to Wolverhampton and thanks to all the people who have helped me to grow during this learning period, also my teammates and the board," he wrote.
His arrival at the team that finished fourth in the classification last season will give support to Youssef En-Nesyri, while probably opening the door for Luuk de Jong to return to the Netherlands.
The move is estimated to have cost Sevilla around 15 million euros with Mir signing a contract until the end of June 2027.
Source : Xinuha

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025